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Following relapse on endocrine therapy for advanced, hormone receptor-positive breast cancer, it is common for patients to
experience responses to alternative endocrine agents. Fulvestrant (‘Faslodex’) is a new type of endocrine treatment – an oestrogen
receptor (ER) antagonist with no agonist effects. Fulvestrant downregulates cellular levels of the ER resulting in decreased expression
of the progesterone receptor. This unique mode of action means that it is important that fulvestrant is placed optimally within the
sequence of endocrine therapies to ensure that patients gain maximum benefit. Fulvestrant has shown efficacy when used after
progression on tamoxifen or anastrozole in postmenopausal women with advanced breast cancer. After progression on fulvestrant,
subsequent endocrine treatments can produce responses in many patients, demonstrating that fulvestrant does not lead to
crossresistance with other endocrine therapies. Responses to fulvestrant have also been observed in patients heavily pretreated with
prior endocrine therapy. Fulvestrant is a versatile endocrine agent that may be integrated into the therapeutic sequence prior to, or
subsequent to, other hormonal therapies, and represents a valuable additional antioestrogen for the treatment of postmenopausal
women with advanced breast cancer.
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The efficacy and tolerability advantages associated with the use of
endocrine agents in the treatment of hormone receptor-positive
advanced breast cancer have been clearly established in many
clinical studies. However, despite an initial response, many
patients will eventually experience disease progression and require
further endocrine treatment options. In patients who respond to
endocrine treatments, additional responses to further agents are
common (Buzdar and Hortobagyi, 1998; Hortobagyi, 1998). This
potential responsiveness to multiple endocrine therapies means
that patients may continue to derive clinical benefit while avoiding
the marked, and often distressing, adverse side effects associated
with chemotherapy. This is a particularly important consideration
in a predominantly elderly patient population who may be least
able to tolerate severe adverse events. Disease control is also
important in this patient group for whom an absolute cure may not
be achievable, and instead, prevention of disease progression and
the maintenance of quality of life may be more important.
The activity of sequential endocrine therapies is dependent upon
them possessing different mechanisms of action. In this way,
crossresistance between sequential therapies may be avoided. It is
therefore important that, as new endocrine therapies with different
mechanisms of action become available, they are integrated
effectively into the sequential hormonal regimens to allow patients
to derive maximum benefit.
FULVESTRANT AND THE ENDOCRINE SEQUENCE
CASCADE
Fulvestrant (‘Faslodex’) is a new type of endocrine treatment – an
oestrogen receptor (ER) antagonist with no agonist effects
(Wakeling et al, 1991; Robertson et al, 2001). Fulvestrant binds
to the ER but, due to its steroidal structure and long side-chain,
induces a different conformational shape with the receptor to that
achieved by the nonsteroidal antioestrogen tamoxifen. As a result
of this, fulvestrant prevents ER dimerisation and leads to the rapid
degradation of the fulvestrant–ER complex, producing the loss of
cellular ER (Borras et al, 1996). As a result, fulvestrant (unlike
tamoxifen) inhibits ER–DNA binding and produces abrogation of
oestrogen-sensitive gene transcription (Dauvois et al, 1993).
The unique mode of action of fulvestrant presents a useful
addition to the endocrine agents currently available for use in
sequential therapeutic regimens. Fulvestrant has been approved in
the United States and Brazil for the treatment of hormone
receptor-positive metastatic breast cancer in postmenopausal
women with disease progression following antioestrogen therapy.
An increasing number of studies are demonstrating the versatility
of fulvestrant for the treatment of advanced breast cancer (Howell
et al, 2002; Osborne et al, 2002; Perey et al, 2002; Steger et al,
2003a,b). An understanding and appreciation of these data will be
important for determining the optimal placing of fulvestrant in the
sequence cascade of hormonal therapy.
Efficacy post-tamoxifen
The efficacy of fulvestrant has been proven in two phase III trials
conducted in postmenopausal patients with hormone-sensitive
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these trials, the efficacy of fulvestrant was comparable to the highly
selective, third-generation aromatase inhibitor (AI) anastrozole
(‘Arimidex’) (Howell et al, 2002; Osborne et al, 2002). Fulvestrant
is the only antioestrogen acting directly on ER that has
demonstrated efficacy post-tamoxifen, illustrating the lack of
crossresistance between these two therapies. This is in contrast to
the selective oestrogen receptor modulators (SERMs) such as
droloxifene, idoxifene, toremifene, and benzothiophene arzoxi-
fene, all of which have shown minimal activity in tamoxifen-
resistant disease (Johnston, 2001).
Efficacy post-AI
Owing to their improved efficacy and tolerability, AIs are
increasingly being used in the first-line treatment of breast cancer,
in both early and advanced disease (Nabholtz et al, 2000; ATAC
Trialists’ Group, 2002; Mouridsen et al, 2003). Preclinical data
indicate that exposure to long-term oestrogen deprivation (similar
to that caused by AIs) and subsequent development of acquired
resistance may be accompanied by adaptive increases in ER gene
expression and intercellular signalling, resulting in hypersensitiv-
ity to low oestradiol levels (Jeng et al, 1998; Shim et al, 2000; Chan
et al, 2002; Martin et al, 2003). In this situation, tamoxifen may be
perceived as an agonist. As a result, it is important to establish the
efficacy of fulvestrant after progression on AIs. In vitro, fulvestrant
significantly inhibited the expression of genes such as c-myb and
c-myc in cells resistant to long-term oestrogen deprivation (Jeng
et al, 1998) and may therefore be an appropriate therapeutic
option after progression on AIs.
Clinical data so far are limited, but preliminary results from an
ongoing phase II study have shown that fulvestrant produced
clinical benefit (CB, complete response (CR)þpartial response
(PR)þstable disease (SD) X24 weeks) in seven out of 17 (41%)
patients who had received, and had progressed on, prior treatment
with tamoxifen and an AI (Perey et al, 2002). These results suggest
that in addition to producing responses after prior tamoxifen,
disease progression after anastrozole may not preclude subsequent
treatment with fulvestrant. Further trials in this setting are now in
progress and are discussed later in this paper.
Efficacy in heavily pretreated patients
Many patients may receive a number of different endocrine
therapies as well as chemotherapies during the course of their
disease. Preliminary data are becoming available from centres
using fulvestrant in Named Patient Programmes involving
patients heavily pretreated with endocrine therapies including
tamoxifen, anastrozole, letrozole, exemestane, and goserelin.
In 67 postmenopausal women with metastatic breast cancer, 64
of whom (96%) had progressed on one, two or three prior
endocrine agents for advanced disease, fulvestrant produced CB in
40 patients (60%) overall. A total of six patients (9%) derived a PR.
Of these, one had received fulvestrant as first-line therapy for
advanced disease, two had received fulvestrant as second-line
therapy, and three had received it as third-line therapy. No
objective responses were seen in patients receiving fourth-line
fulvestrant therapy. This might suggest that fulvestrant produces
better responses when given earlier in the treatment sequence
(Steger et al, 2003a).
Similar results have been obtained in a separate single-centre
study. Postmenopausal women with metastatic breast cancer who
had been heavily pretreated with prior hormonal therapy
(including tamoxifen, AIs, androgens, and high-dose oestrogens)
and chemotherapy (including taxanes, capecitabine, doxorubicin,
and cisplatin) were treated with fulvestrant; SD X24 weeks was
achieved in eight out of 42 (19%) patients (Franco et al, 2003).
Endocrine therapy after progression on fulvestrant
Two studies have provided evidence that the marked reduction in
ER expression produced by fulvestrant is not associated with
crossresistance to subsequent endocrine therapies (Howell, 2002;
Vergote et al, 2003). These studies used the retrospective analysis
of data derived from questionnaires sent to clinicians who were
involved in trials of fulvestrant as first- or second-line therapy
(Osborne et al, 2002; Robertson et al, 2002). This methodology
imposes certain limitations on the analyses. However, the
information obtained from these studies does provide further
evidence with regard to establishing sequencing regimens.
Responses to subsequent endocrine therapy in patients who
progressed on fulvestrant or tamoxifen as first-line therapy for
advanced disease have been examined in a retrospective analysis
(Howell, 2002). The limitations of this analysis are illustrated by
the fact that while 170 patients derived CB on fulvestrant, follow-
up data on patients who received subsequent endocrine therapy
were available for only 35 of these. In these patients, subsequent
endocrine therapy produced CB in 20 out of 35 (57%) patients,
with AI-based therapy producing CB in 11 out of 22 (50%) patients
(Table 1). It is interesting to note that in those patients who failed
to derive CB from fulvestrant, subsequent endocrine therapy
produced a similar number of responses to those seen in patients
who did derive CB from fulvestrant (15 out of 35 (43%) and 20 out
of 35 (57%), respectively; Table 2). While the selection of patients
and patient numbers included in this analysis are limited by the
nature of the data collection, they do indicate that responses may
be obtained with AIs and other endocrine therapies after
progression on fulvestrant.
In another retrospective analysis, 186 patients in total derived
CB on second-line fulvestrant, although questionnaire-based
follow-up data were available for only 54 of these patients (Vergote
et al, 2003). The results showed that treatment with endocrine
therapy (predominantly AIs) after second-line fulvestrant pro-
duced CB in 25 out of 54 (46%) patients and objective response
(OR, CRþPR) in four out of 54 (7%) patients who obtained CB
with second-line fulvestrant (Table 1). In patients who failed to
derive CB from second-line fulvestrant, further endocrine therapy
produced CB in 18 out of 51 (35%) patients and OR in one out of
51 (2%) patients (Table 2). Preliminary analyses demonstrated a
median duration of response to subsequent therapy of 383 and 318
days, for patients who did and who did not derive CB from second-
line fulvestrant, respectively. Further endocrine therapy after
progression on fulvestrant is therefore a viable and effective
therapeutic option, with responses seen in patients treated with
Table 1 Response to subsequent therapy in patients who derived clinical
benefit (CB) from fulvestrant
Number of patients
CR PR SD X24 weeks PD Total
Patients who derived CB from first-line fulvestrant
Endocrine therapy total 1 2 17 15 35
Aromatase inhibitors 1 1 9 11 22
Tamoxifen 0 1 7 2 10
Megestrol acetate 0 0 1 0 1
Medroxyprogesterone acetate 0 0 0 2 2
Patients who derived CB from second-line fulvestrant
Endocrine therapy total 0 4 21 29 54
Aromatase inhibitors 0 3 16 27 46
Megestrol acetate 0 1 5 2 8
Adapted from Howell (2002) with permission of Breast Cancer Research and
Treatment (Vergote et al, 2003). CR¼complete response; PR¼partial response;
SD¼stable disease; PD¼progressive disease.
Fulvestrant and the sequential endocrine cascade
S Johnston
S16
British Journal of Cancer (2004) 90(Suppl 1), S15–S18 & 2004 Cancer Research UKtamoxifen and megestrol acetate as well as AIs such as anastrozole
and letrozole.
DISCUSSION
It is important to be aware of the sequence versatility of fulvestrant
so that it may be effectively and appropriately incorporated into
the endocrine sequence cascade. Fulvestrant has demonstrated
efficacy in the treatment of postmenopausal women with
advanced, hormone-sensitive breast cancer, with data indicating
that fulvestrant exhibits this activity in both the post-tamoxifen
and postanastrozole setting. More specifically, fulvestrant has
been shown to be at least as effective as anastrozole in women
with hormone-sensitive disease who have progressed on
first-line therapy (mainly tamoxifen) (Howell et al, 2002;
Osborne et al, 2002; Robertson et al, 2003), with preliminary
data showing promising results after progression on AIs
(Perey et al, 2002). Fulvestrant has also been used in patients
pretreated with several endocrine agents as well as chemo-
therapy. In one report, an overall CB rate of 60% was obtained,
although patients who were treated with fulvestrant earlier
in the sequence appeared to obtain better responses than
those who received it after progression on three endocrine agents
(Steger et al, 2003a).
In patients who undergo disease progression on fulvestrant, the
novel mode of action of this new endocrine therapy ensures a lack
of crossresistance to other current endocrine agents (Howell, 2002;
Vergote et al, 2003). Thus, the early use of fulvestrant in the
sequence of endocrine therapies may not limit later choices of
endocrine therapy. Fulvestrant can, therefore, potentially be
integrated into sequential endocrine regimens at a number of
positions, including the second-line setting after tamoxifen, or,
potentially, after AIs (Figure 1). Endocrine therapies such as
megestrol acetate or the steroidal AI exemestane may then be
employed as necessary after progression on fulvestrant. In this
way, the potentially most effective and well-tolerated agents are
used earlier in the treatment sequence.
To optimise the positioning of fulvestrant in the sequence of
endocrine therapies, additional studies will be required to
elaborate upon the data so far accrued. New phase II and III
clinical trials of fulvestrant in over 3000 patients are either planned
or currently in progress (Table 3). These will investigate additional
roles for fulvestrant in breast cancer therapy, either following prior
nonsteroidal AI treatment or in combination with AIs as first-line
therapy. In addition, loading-dose fulvestrant regimens will be
tested. Two randomised, controlled trials are comparing the
efficacy and tolerability of fulvestrant vs exemestane in post-
menopausal women progressing after long-term oestrogen depri-
vation resulting from prior AI therapy. The primary aim of the
Study Of Faslodex vs Exemestane with/without Arimidex (SOFEA)
trial is to compare progression-free survival in patients who have
progressed on a nonsteroidal AI, and who are subsequently treated
with either fulvestrant plus continued anastrozole, or with
fulvestrant alone. Secondary aims include a comparison of
fulvestrant vs exemestane and an examination of biological
markers of response. A further trial, the Evaluation of Faslodex
vs Exemestane Clinical Trial (EFECT) is currently recruiting
patients to assess the efficacy of fulvestrant vs exemestane in
patients who have progressed on treatment with nonsteroidal AIs.
In addition, two trials (FACT and SWOG 226) will compare the
efficacy of a combination of fulvestrant plus anastrozole with
anastrozole alone in the first-line setting (Table 3). The results of
Table 2 Response to subsequent therapy in patients who did not derive
clinical benefit (CB) from fulvestrant
Number of patients
CR PR SD X24 weeks PD Total
Patients who did not derive CB from first-line fulvestrant
Endocrine therapy total 0 3 12 20 35
Aromatase inhibitors 0 0 8 11 19
Tamoxifen 0 3 2 7 12
Megestrol acetate 0 0 1 0 1
Medroxyprogesterone acetate 0 0 1 2 3
Patients who did not derive CB from second-line fulvestrant
Endocrine therapy total 0 1 17 33 51
Aromatase inhibitors 0 1 15 26 42
Megestrol acetate 0 0 1 5 6
Medroxyprogesterone acetate 0 0 1 2 3
Adapted from Howell (2002) with permission of Breast Cancer Research and
Treatment. (Vergote et al, 2003). CR¼complete response; PR¼partial response;
SD¼stable disease; PD¼progressive disease.
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Figure 1 Proposed positions of fulvestrant within the available
endocrine therapies for the sequential treatment of postmenopausal
women with hormone receptor-positive, advanced disease. Adapted from
Carlson (2002) with permission of Breast Cancer Research and Treatment.
Table 3 New phase II/III clinical trials of fulvestrant in over 3000 breast cancer patients
Trial Phase Population Treatments Patients (n)
NCCTG II Post-tamoxifen or post-AIs Fulvestrant 250mg 89
SAKK II Post-tamoxifen or post-AIs Fulvestrant 250mg 93
EFECT III Post-nonsteroidal AI Fulvestrant LD 250mg vs exemestane 660
SOFEA III Post-nonsteroidal AI Fulvestrant LD 250mg7anastrozole vs exemestane 750
FACT III First-line Fulvestrant LD 250mg+anastrozole vs anastrozole 558
SWOG 226 III First-line Fulvestrant 250mg+anastrozole vs anastrozole 690
0057 II Neoadjuvant Fulvestrant 250mg+anastrozole vs anastrozole 120
FAST II Neoadjuvant Fulvestrant HD vs tamoxifen 60
NCCTG¼North Central Cancer Treatment Group; SAKK¼Swiss Group for Clinical Cancer Research; EFECT¼Evaluation of Faslodex vs Exemestane Clinical Trial;
SOFEA¼Study Of Faslodex vs Exemestane with/without Arimidex; SWOG¼Southwest Oncology Group; LD 250mg¼loading-dose schedule of fulvestrant: 500mg day 0,
250mg days 14 and 28, fulvestrant 250mg per monthly thereafter; HD¼high-dose schedule of fulvestrant 750mg 2–3 weeks presurgery.
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strategies, particularly as AIs move forward into the first-line or
adjuvant settings.
Currently available data therefore indicate that fulvestrant will
be a useful therapeutic option that may extend the opportunity for
using endocrine therapies before reliance upon cytotoxic che-
motherapy is necessary. Fulvestrant is also a versatile endocrine
therapy that may be used at a variety of positions in the sequential
use of endocrine therapy for postmenopausal women with
advanced, hormone-sensitive breast cancer.
REFERENCES
ATAC Trialists’ Group (2002) Anastrozole alone or in combination with
tamoxifen versus tamoxifen alone for adjuvant treatment of postmeno-
pausal women with early breast cancer: first results of the ATAC
randomised trial. Lancet 359: 2131–2139
Borras M, Laios I, el Khissiin A, Seo HS, Lempereur F, Legros N, Leclercq G
(1996) Estrogenic and antiestrogenic regulation of the half-life of
covalently labeled estrogen receptor in MCF-7 breast cancer cells. J
Steroid Biochem Mol Biol 57: 203–213
Buzdar AU, Hortobagyi G (1998) Update on endocrine therapy for breast
cancer. Clin Cancer Res 4: 527–534
Carlson RW (2002) Sequencing of endocrine therapies in breast cancer –
integration of recent data. Breast Cancer Res Treat 75(Suppl 1): S27–S32
Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M (2002) Molecular
changes associated with the acquisition of oestrogen hypersensitivity in
MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid
Biochem Mol Biol 81: 333–341
Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780
disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci
106(Part 4): 1377–1388
Franco S, Perez A, Tan-Chiu E, Frankel C, Vogel C (2003) Fulvestrant
(Faslodex
s) demonstrates clinical benefit in heavily pretreated post-
menopausal women with advanced breast cancer: a single-center
experience. Breast Cancer Res Treat 82(Suppl 1): S105 (abstract 429)
Hortobagyi GN (1998) Progress in endocrine therapy for breast carcinoma.
Cancer 83: 1–6
Howell A (2002) Postmenopausal women with advanced breast cancer
who progress on fulvestrant or tamoxifen retain sensitivity to
further endocrine therapies. Breast Cancer Res Treat 76(Suppl 1): S72
(abstract 251)
Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac
L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002)
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in
postmenopausal women with advanced breast cancer progressing after
prior endocrine treatment. J Clin Oncol 20: 3396–3403
Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar
R, Masamura S, Santen RJ (1998) Estrogen receptor expression and
function in long-term estrogen-deprived human breast cancer cells.
Endocrinology 139: 4164–4174
Johnston SR (2001) Endocrine manipulation in advanced breast
cancer: recent advances with SERM therapies. Clin Cancer Res 7:
4376s–4387s
Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M (2003)
Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal
transduction pathways operate during the adaptation of MCF-7 cells to
long term estrogen deprivation. J Biol Chem 278: 30458–30468
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier
A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank
M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang
R, Wyld P, Bhatnagar A (2003) Phase III study of letrozole versus
tamoxifen as first-line therapy of advanced breast cancer in postmeno-
pausal women: analysis of survival and update of efficacy from the
International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101–2109
Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A,
Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to
tamoxifen as first-line therapy for advanced breast cancer in post-
menopausal women: results of a North American multicenter rando-
mized trial. Arimidex Study Group. J Clin Oncol 18: 3758–3767
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ,
May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A
(2002) Double-blind, randomized trial comparing the efficacy and
tolerability of fulvestrant versus anastrozole in postmenopausal women
with advanced breast cancer progressing on prior endocrine therapy:
results of a North American trial. J Clin Oncol 20: 3386–3395
Perey L, Thu ¨rlimann B, Hawle H, Bonnefoi H, Ahern J, Pagani O,
Goldhirsch A, Dietrich D (2002) Fulvestrant (‘faslodex’) as hormonal
treatment in postmenopausal patients with advanced breast cancer
progressing after treatment with tamoxifen and aromatase inhibitors.
Breast Cancer Res Treat 76(Suppl 1): S72 (abstract 249)
Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M,
Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M (2001)
Comparison of the short-term biological effects of 7-alpha-[9-(4,4,5,5,5-
pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol
(Faslodex) versus tamoxifen in postmenopausal women with primary
breast cancer. Cancer Res 61: 6739–6746
Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M,
Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A,
Morris C (2003) Fulvestrant versus anastrozole for the treatment of
advanced breast carcinoma in postmenopausal women – a prospective
combined analysis of two multicenter trials. Cancer 98: 229–238
Robertson JFR, Howell A, Abram P, Lichinitser M, Elledge R (2002)
Fulvestrant versus tamoxifen for the first-line treatment of advanced
breast cancer (ABC) in postmenopausal women. Ann Oncol 13(Suppl 5):
46 (abstract 164O)
Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R, Santen RJ
(2000) Estradiol hypersensitivity and mitogen-activated protein kinase
expression in long-term estrogen deprived human breast cancer cells in
vivo. Endocrinology 141: 396–405
Steger G, Bartsch R, Wenzel C, Pluschnig U, Locker G, Mader RM, Zielinski
CC (2003a) Fulvestrant (‘Faslodex’) demonstrates clinical benefit in
heavily pre-treated patients with metastatic breast cancer. Eur J Cancer
1(Suppl 5): S135
Steger G, Bartsch R, Wenzel C, Pluschnig U, Locker G, Mader RM, Zielinski
CC (2003b) Fulvestrant beyond the second hormonal treatment line in
metastatic breast cancer. Proc Am Soc Clin Oncol 22: 20
Vergote I, Robertson JFR, Kleeberg U, Burton G, Osborne CK, Mauriac L
(2003) Postmenopausal women who progress on fulvestrant (‘Faslodex’)
remain sensitive to further endocrine therapy. Breast Cancer Res Treat
79: 207–211
Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen
with clinical potential. Cancer Res 51: 3867–3873
Fulvestrant and the sequential endocrine cascade
S Johnston
S18
British Journal of Cancer (2004) 90(Suppl 1), S15–S18 & 2004 Cancer Research UK